By SPC News Staff
In an effort to make the drug more affordable to Medicare patients, Sanofi and Regeneron said they will lower the cost of alirocumab (Praluent) by more than half beginning in March.
The new U.S. National Drug Code list price will be $5,850 annually, a 60% reduction from the original price, for both the 75- and 150-mg doses. Out-of-pocket costs for Medicare patients could be lowered to approximately $25 to $150 per month, a potential savings of up to $345 depending on their